Cambridge Consultants and India’s Sun Pharma Advanced Research Company (SPARC) have developed a new dry powder inhaler. According to the companies, the device delivers an even, consistent drug dose deep into the lungs regardless of how strong the inhalation is performed by the patient.
From the press release:
The device employs a novel de-agglomeration engine to separate the drug from the lactose ‘carrier’ particles. Based on a highly efficient airway design, the patented drug separation mechanism has successfully completed clinical trials and demonstrated that it is capable of delivering significantly more of the drug to the deep lung than traditional inhalers. In practice, this will minimise side effects from drug build-up in the back of the throat, reduce non-systemic load and wastage, and means almost 50% less active drug needs pre-loading into the device in comparison to a standard inhaler. Read more »
*This blog post was originally published at Medgadget*